Skip to content
Evofem Biosciences, Inc.
About Us
Mission
Management
Board of Directors
Saundra Pelletier
KIM P. KAMDAR, Ph.D.
Tony O’Brien
Lisa Rarick, MD, FACOG
Colin Rutherford
Our Product
phexxi
®
Pipeline
In Development
Posters & Publications
Investors
Investor Overview
Events & Presentations
Press Releases
Stock Information
Financial Information
SEC Filings
Analyst Coverage
Corporate Governance
Committee Composition
Board of Directors
Charters + Code of Ethics
Investor Resources
Investor Contact
Investor FAQs
Contact
Investor Contact
Media Contact
General Contact
Careers
Sexual Satisfaction With a Vaginal pH Regulator (EVO100): Results From the AMPREVENCE Clinical Trial
Post navigation
Previous:
Characterization of Women According to Their Sexual Satisfaction After Treatment With the Novel Vaginal pH Regulator (VPR™) During the AMPOWER Study
Next:
Genitourinary Side Effects With Vaginal pH Regulator: Results From AMPOWER
Back
to
Top
